61 related articles for article (PubMed ID: 22193919)
1. Alterations in the common pathway of coagulation during weight loss induced by gastric bypass in severely obese patients.
Pardina E; Ferrer R; Rivero J; Baena-Fustegueras JA; Lecube A; Fort JM; Vargas V; Catalán R; Peinado-Onsurbe J
Obesity (Silver Spring); 2012 May; 20(5):1048-56. PubMed ID: 22193919
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD40 ligand in morbidly obese patients: effect of body mass index on recovery to normal levels after gastric bypass surgery.
Baena-Fustegueras JA; Pardina E; Balada E; Ferrer R; Catalán R; Rivero J; Casals I; Lecube A; Fort JM; Vargas V; Peinado-Onsurbe J
JAMA Surg; 2013 Feb; 148(2):151-6. PubMed ID: 23426590
[TBL] [Abstract][Full Text] [Related]
3. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
4. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation.
Alessi MC; Bastelica D; Mavri A; Morange P; Berthet B; Grino M; Juhan-Vague I
Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1262-8. PubMed ID: 12750120
[TBL] [Abstract][Full Text] [Related]
5. Increased serum amyloid A concentrations in morbid obesity decrease after gastric bypass.
Gómez-Ambrosi J; Salvador J; Rotellar F; Silva C; Catalán V; Rodríguez A; Jesús Gil M; Frühbeck G
Obes Surg; 2006 Mar; 16(3):262-9. PubMed ID: 16545156
[TBL] [Abstract][Full Text] [Related]
6. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity.
Primrose JN; Davies JA; Prentice CR; Hughes R; Johnston D
Thromb Haemost; 1992 Oct; 68(4):396-9. PubMed ID: 1448769
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss.
Mavri A; Alessi MC; Bastelica D; Geel-Georgelin O; Fina F; Sentocnik JT; Stegnar M; Juhan-Vague I
Diabetologia; 2001 Nov; 44(11):2025-31. PubMed ID: 11719834
[TBL] [Abstract][Full Text] [Related]
8. Changes in leptin, plasminogen activator factor and oxidative stress in morbidly obese patients following open and laparoscopic Swedish adjustable gastric banding.
Uzun H; Zengin K; Taskin M; Aydin S; Simsek G; Dariyerli N
Obes Surg; 2004 May; 14(5):659-65. PubMed ID: 15186635
[TBL] [Abstract][Full Text] [Related]
9. Serum amyloid A: a marker of adiposity-induced low-grade inflammation but not of metabolic status.
Poitou C; Coussieu C; Rouault C; Coupaye M; Cancello R; Bedel JF; Gouillon M; Bouillot JL; Oppert JM; Basdevant A; Clément K
Obesity (Silver Spring); 2006 Feb; 14(2):309-18. PubMed ID: 16571858
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
[TBL] [Abstract][Full Text] [Related]
11. Serum retinol-binding protein 4 is not increased in obesity or obesity-associated type 2 diabetes mellitus, but is reduced after relevant reductions in body fat following gastric bypass.
Gómez-Ambrosi J; Rodríguez A; Catalán V; Ramírez B; Silva C; Rotellar F; Gil MJ; Salvador J; Frühbeck G
Clin Endocrinol (Oxf); 2008 Aug; 69(2):208-15. PubMed ID: 18081728
[TBL] [Abstract][Full Text] [Related]
12. Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype.
Estellés A; Dalmau J; Falcó C; Berbel O; Castelló R; España F; Aznar J
Thromb Haemost; 2001 Aug; 86(2):647-52. PubMed ID: 11522017
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery.
Tschoner A; Sturm W; Engl J; Kaser S; Laimer M; Laimer E; Klaus A; Patsch JR; Ebenbichler CF
Nutr Metab Cardiovasc Dis; 2012 Apr; 22(4):340-6. PubMed ID: 21093232
[TBL] [Abstract][Full Text] [Related]
14. Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity.
Malavazos AE; Ermetici F; Cereda E; Coman C; Locati M; Morricone L; Corsi MM; Ambrosi B
Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):523-30. PubMed ID: 18083357
[TBL] [Abstract][Full Text] [Related]
15. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines.
He G; Andersen O; Haugaard SB; Lihn AS; Pedersen SB; Madsbad S; Richelsen B
Eur J Clin Invest; 2005 Sep; 35(9):583-90. PubMed ID: 16128865
[TBL] [Abstract][Full Text] [Related]
17. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals.
Eriksson P; Reynisdottir S; Lönnqvist F; Stemme V; Hamsten A; Arner P
Diabetologia; 1998 Jan; 41(1):65-71. PubMed ID: 9498632
[TBL] [Abstract][Full Text] [Related]
18. Adipocyte fatty acid-binding protein as a determinant of insulin sensitivity in morbid-obese women.
Simón I; Escoté X; Vilarrasa N; Gómez J; Fernández-Real JM; Megía A; Gutiérrez C; Gallart L; Masdevall C; Vendrell J
Obesity (Silver Spring); 2009 Jun; 17(6):1124-8. PubMed ID: 19197257
[TBL] [Abstract][Full Text] [Related]
19. Effect of bariatric surgery on peripheral blood lymphocyte subsets in women.
Merhi ZO; Durkin HG; Feldman J; Macura J; Rodriguez C; Minkoff H
Surg Obes Relat Dis; 2009; 5(2):165-71. PubMed ID: 18996763
[TBL] [Abstract][Full Text] [Related]
20. Differential response of plasma plasminogen activator inhibitor 1 after weight loss surgery in patients with or without type 2 diabetes.
Mossberg KE; Pournaras DJ; Welbourn R; le Roux CW; Brogren H
Surg Obes Relat Dis; 2017 Jan; 13(1):53-57. PubMed ID: 27387691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
